- Home
- AUPH vs GHRS Comparison
AUPH vs GHRS Comparison
Compare AUPH & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUPH | GHRS |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AUPH | GHRS |
|---|---|---|
| Price | $16.65 | $28.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $17.25 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 1.2M | 322.3K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5075.00 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $283,055,000.00 | N/A |
| Revenue This Year | $17.54 | N/A |
| Revenue Next Year | $15.74 | N/A |
| P/E Ratio | $32.58 | ★ N/A |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $10.34 | $11.83 |
| 52 Week High | $19.25 | $31.44 |
Technical Indicators
Market Signals| Indicator | AUPH | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 48.98 |
| Support Level | $14.67 | $28.05 |
| Resistance Level | $19.25 | $28.96 |
| Average True Range (ATR) | 0.58 | 1.50 |
| MACD | 0.20 | -0.24 |
| Stochastic Oscillator | 65.63 | 11.46 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.